Report adverse events:

Adverse events should be reported to the Vifor Pharma group.
safety@viforpharma.com

Send email

Providing sustained, around the clock control of your patients’ K+, and proven to enable guideline-recommended RAASi treatment, Veltassa® is reliable and easy to use with no sodium-associated risk1–7

Find out more about the reliability and ease of use of Veltassa®

K+ control with Veltassa®

  • Chronic hyperkalaemia is a serious medical condition associated with high morbidity and mortality.8-13
  • RAASi treatment exacerbates the risk of hyperkalaemia.14
  • Guideline-recommended RAASi treatment improves outcomes in patients with CKD and heart failure.14-24
  • Stopping or discontinuing RAASi is associated with worse outcomes25

Reliable

 
  • Proven to enable guideline-recommended RAASi treatment1,4,5,20,26
  • Reduces K+ levels from the first dose3
  • Sustained long-term K+ control2

Easy
to use

 
  • Once-daily dosing from the start7
  • Can be taken with apple or cranberry juice to suit individual tastes7

No Na+
risk

 
  • No additional CV and renal risk due to Na+6

icon

Sustained K+ control in
up to 95% of patients2

icon

Effective regardless
of HK severity1

icon

Round the clock
protection3

icon

RAASi
enablement1,4,5,20,26
icon
Understand why reliable K+ control is important

HOW VELTASSA® WORKS

  • Veltassa® exchanges K+ for Ca2+, making it suitable for patients who cannot tolerate even a small increase in Na+ load.6,7
  • Veltassa® is specifically designed to act in the colon where the concentration of K+ is highest.6,7
MOA video

icon

Hypokalaemia has not
been identified as an
ADR for Veltassa®7

icon

No dose-related oedema
observed in over 52
weeks of treatment2

icon

Positive risk/benefit
profile in clinical trials
and real world practice7
icon
Learn more about Veltassa®

Simple and easy once-daily dosing

1

MIX

Information on how to take Veltassa: Step 1 MIX

Mix 3 tablespoons of water with an entire sachet of Veltassa®, then stir

2

ADD

Information on how to take Veltassa: Step 2 ADD

Add another 3 tablespoons of water and stir thoroughly. The powder will not dissolve and the mixture will look cloudy

3

DRINK

Information on how to take Veltassa: Step 3 DRINK

Drink immediately. If powder remains in the glass after drinking, repeat steps 2 and 3 to ensure the entire dose is taken

  • The recommended starting dose of 1 x 8.4 g sachet per day is effective in >90% of patients7,27
  • Veltassa® can be taken with apple or cranberry juice to suit individual tastes7
icon
Read up on the clinical experience with Veltassa®

References & footnotes

ADR, adverse drug reaction; Ca2+, calcium ions; CKD, chronic kidney disease; CV, cardiovascular; HK, hyperkalaemia; K+, potassium ions; MOA, mechanism of action; Na+, sodium ions; RAASi, renin-angiotensin-aldosterone system inhibitors.

Footnotes:

Veltassa® is indicated for the treatment of hyperkalaemia in adults.7

References:

1. Weir MR, et al. N Engl J Med 2015;372(3):211–21. 2. Bakris GL, et al. JAMA 2015;314(2):151–61. 3. Bushinsky DA, et al. Kidney Int 2015;88:1427–33. 4. Pitt B, et al. Eur Heart J 2011;32:820–8. 5. Agarwal R, et al. Lancet 2019;394(10208):1540−50. 6. Li L, et al. J Card Pharmacol Ther 2016;21(5):456–65. 7. Veltassa® EU SmPC, 2019. 8. Di Lullo L, et al. Cardiorenal Med 2019;9(1):8−21. 9. Rastegar A, Soleimani M. Postgrad Med J 2001;77(914):759−64. 10. Kjeldsen KP, Schmidt TA. Eur Heart J 2019;21(Suppl A):A2−A5. 11. Collins AJ, et al. Am J Nephrol 2017;46(3):213−21. 12. Kovesdy CP, et al. Eur Heart J 2018;39(17):1535−42. 13. Rossignol P, et al. Clin Kidney J 2020;13:714−9. 14. Palmer BF, et al. N Engl J Med 2004;351:585–92. 15. KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020;98(Suppl 4S):S1–S116. 16. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1–150. 17. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. 2004. Available at: kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_bp/index.htm (accessed July 2020). 18. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355(9200):253−9. 19. SOLVD Investigators. N Engl J Med 1991;325(5):293−302. 20. Desai AS, et al. J Am Coll Cardiol 2007;50(20):1959−66. 21. Pitt B, et al. N Engl J Med 1999;341(10):709−17. 22. Zannad F, et al. N Engl J Med 2011;364:11–21. 23. McMurray JJ, et al. N Engl J Med 2014;371(11):993−1004. 24. Solomon SD, et al. N Engl J Med 2019;381(17):1609−20.  25. Epstein M, et al. Am J Manag Care 2015;21(11 Suppl):S212−S220. 26. Kovesdy CP, et al. Postgrad Med 2020;132:176–83. 27. Data on file. Healthcare Analytics (SHA), a Symphony Health Solutions Corporation (February 2019).